Dr Dilip Surana, CMD of Micro Labs Limited, hails tariff shield as a landmark step that strengthens India’s $9 billion pharma exports to the US, meeting nearly half of America’s generic drug demand while easing patient cost burdens. New Delhi/Washington – The India–US bilateral trade
Recent Posts
- Trusted by His Tribe, Distrusted by the Nation: The Trump Paradox
- Iran War Sparks Pharma Shockwaves: India Faces $500 Million Export Hit
- The $100 Barrel: How a New Supreme Leader and a Closed Strait Are Redrawing the Global Power Map
- Trump’s Reign Of Chaos: Is He A Threat To World Peace?
- Global Oil Crisis Deepens: War Between Iran, U.S. & Israel Sparks Emergency










